Salvia BioElectronics Secures $60M Series B to Pioneer Migraine Therapy
Deal News | Jun 02, 2025 | Innovation Industries Manageme
Salvia BioElectronics, a clinical-stage medical device company based in Eindhoven, has secured $60 million in a Series B funding round to advance its pioneering neuromodulation therapy for chronic migraine sufferers. Led by deeptech venture capital firm Innovation Industries, with contributions from Invest-NL, EIC Fund, and other existing investors, the funding aims to fast-track the commercial launch of MySalvia Therapy. This therapy, currently in clinical trials, features a minimally invasive, patient-controlled approach deploying ultra-thin implants to target migraine-associated nerves. Salvia plans to use the funds for clinical development and to obtain regulatory approval in the US, Europe, and Australia. The company, founded in 2017, is led by industry veterans committed to offering migraine patients an opportunity to regain their lifestyles. Innovation Industries, known for investing in transformative technologies, recognizes the urgency of addressing the global migraine burden, which costs the EU and US economies $110 billion annually. Through strategic partnerships and evaluations, Salvia aims to reshape the migraine treatment landscape.
Sectors
- Medical Devices
- Venture Capital & Private Equity
Geography
- Netherlands – Salvia BioElectronics is headquartered in Eindhoven, making the Netherlands a central geography.
- Europe – The funding includes European investors, and clinical trials are underway in Europe.
- United States – Salvia BioElectronics is seeking FDA approval in the US for MySalvia Therapy.
- Australia – The RECLAIM study is being conducted in Australia as part of Salvia's clinical development.
Industry
- Medical Devices – Salvia BioElectronics is involved in the development of medical devices, specifically neuromodulation implants for migraine therapy.
- Venture Capital & Private Equity – Innovation Industries and other investors are participating in the funding, showcasing the role of venture capital in advancing medical technologies.
Financials
- 60,000,000 USD – Total raised in the Series B funding round by Salvia BioElectronics.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Salvia BioElectronics | Target Company | Company | A clinical-stage medical device company focused on neuromodulation therapy for chronic migraines. |
| Innovation Industries | Lead Investor | Company | A European deeptech venture capital firm leading the Series B funding round for Salvia BioElectronics. |
| Invest-NL | Investor | Company | Contributor to the Series B funding round for Salvia BioElectronics. |
| EIC Fund | Investor | Company | Contributor to the Series B funding round for Salvia BioElectronics. |
| Hubert Martens | CEO and Founder | Person | CEO and founder of Salvia BioElectronics, leading the company in developing MySalvia Therapy. |
| Caaj Greebe | Partner at Innovation Industries | Person | Partner at Innovation Industries, involved in the investment and strategic guidance for Salvia BioElectronics. |